- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05646316
Effekten av kartläggning av Sentinel Lymfkörtel på patienten rapporterad nedre extremitetsdysfunktion i stadium I endometriecancer
En fas III-studie av effekten av kartläggning av Sentinel-lymfkörtel på patienten rapporterad dysfunktion i nedre extremiteter vid endometriecancer
This phase III trial compares the effect of sentinel lymph node mapping to standard lymph node dissection in reducing the risk of swelling in the legs (lymphedema) in patients undergoing a hysterectomy for stage I endometrial cancer. Standard lymph node dissection removes lymph nodes around the uterus during a hysterectomy to look for spread of cancer from the uterus to nearby lymph nodes. Sentinel lymph node mapping uses a special dye and camera to look for cancer that may have spread to nearby lymph nodes. Comparing the results of the procedures may help doctors predict the risk of long-term swelling in the legs.
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
PRIMARY OBJECTIVES:
I. To compare the rates of lower extremity limb dysfunction (defined as a >= 4-point increase in Gynecologic Cancer Lymphedema Questionnaire [GCLQ] symptom score from baseline) in patients with apparent uterine confined endometrial cancer randomized to one of two lymphatic assessment strategies at time of hysterectomy:
Ia. Sentinel lymph node mapping and excision followed by side-specific lymphadenectomy on sides without a sentinel lymph node (SLN) identified according to a National Comprehensive Cancer Network (NCCN) guidelines approved algorithm (Arm 1); Ib. Sentinel lymph node mapping and excision according to an NCCN Guidelines approved algorithm followed by bilateral pelvic +/- para-aortic lymphadenectomy (Arm 2).
SECONDARY OBJECTIVE:
I. To compare changes in lower extremity limb circumference in patients with apparent uterine confined endometrial cancer randomized to one of two lymphatic assessment strategies at time of hysterectomy.
II. To validate the test characteristics of a SLN mapping algorithm including SLN detection rates, rate of perioperative complications, rate of identifying lymphatic metastases, and detection of micrometastases using pathologic ultra-staging.
EXPLORATORY OBJECTIVES:
I. To compare adjuvant therapy decisions in patients with apparent uterine confined endometrial cancer randomized to one of two lymphatic assessment strategies at time of hysterectomy.
II. To explore the impact of patient characteristics (age, body mass index [BMI], race), extent of lymph node dissection, and adjuvant therapy decisions (radiation, chemotherapy) on the development of lower extremity limb dysfunction - as well as their interaction with lymph node assessment strategies.
III. To evaluate the cost-effectiveness of SLN mapping with or without completion of lymphadenectomy for endometrial cancer.
SAFETY OBJECTIVE:
I. To compare progression free and overall survival in patients with apparent uterine confined endometrial cancer randomized to one of two lymphatic assessment strategies at time of hysterectomy.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM 1: Patients receive ICG dye via injection and undergo sentinel lymph node mapping and excision during standard minimally invasive hysterectomy. Lymph nodes around the uterus may be removed if the mapping and excision cannot be completed. Successful mapping requires no additional removal of lymph nodes.
ARM 2: Patients receive ICG dye via injection and undergo sentinel lymph node mapping and excision during standard minimally invasive hysterectomy. Additional lymph nodes around the uterus are removed per standard of care.
Patients in both arms also undergo imaging as clinically indicated and optional blood sample collection throughout the study.
After completion of study intervention, patients are followed every 3 months for one year and at 18 and 24 months.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
District of Columbia
-
Washington D.C., District of Columbia, Förenta staterna, 20037
- Upphängd
- George Washington University Medical Center
-
-
Florida
-
Coral Gables, Florida, Förenta staterna, 33146
- Rekrytering
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Kontakt:
- Site Public Contact
- Telefonnummer: 305-243-2647
-
Huvudutredare:
- Abdulrahman Sinno
-
Deerfield Beach, Florida, Förenta staterna, 33442
- Rekrytering
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Kontakt:
- Site Public Contact
- Telefonnummer: 305-243-2647
-
Huvudutredare:
- Abdulrahman Sinno
-
Doral, Florida, Förenta staterna, 33166
- Rekrytering
- UM Sylvester Comprehensive Cancer Center at Doral
-
Huvudutredare:
- Abdulrahman Sinno
-
Kontakt:
- Site Public Contact
- E-post: kginnity@med.miami.edu
-
Miami, Florida, Förenta staterna, 33136
- Rekrytering
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 305-243-2647
-
Huvudutredare:
- Abdulrahman Sinno
-
Miami, Florida, Förenta staterna, 33176
- Rekrytering
- UM Sylvester Comprehensive Cancer Center at Kendall
-
Kontakt:
- Site Public Contact
- Telefonnummer: 305-243-2647
-
Huvudutredare:
- Abdulrahman Sinno
-
North Miami, Florida, Förenta staterna, 33181
- Rekrytering
- University of Miami Sylvester Comprehensive Cancer Center at Sole Mia
-
Huvudutredare:
- Abdulrahman Sinno
-
Kontakt:
- Site Public Contact
- E-post: kginnity@med.miami.edu
-
Plantation, Florida, Förenta staterna, 33324
- Rekrytering
- UM Sylvester Comprehensive Cancer Center at Plantation
-
Kontakt:
- Site Public Contact
- Telefonnummer: 305-243-2647
-
Huvudutredare:
- Abdulrahman Sinno
-
-
Georgia
-
Augusta, Georgia, Förenta staterna, 30912
- Rekrytering
- Augusta University Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 706-721-2388
- E-post: ga_cares@augusta.edu
-
Huvudutredare:
- Robert V. Higgins
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60611
- Rekrytering
- Northwestern University
-
Kontakt:
- Site Public Contact
- Telefonnummer: 312-695-1301
- E-post: cancer@northwestern.edu
-
Huvudutredare:
- Emily Hinchcliff
-
Warrenville, Illinois, Förenta staterna, 60555
- Rekrytering
- Northwestern Medicine Cancer Center Warrenville
-
Kontakt:
- Site Public Contact
- Telefonnummer: 630-352-5360
- E-post: Donald.Smith3@nm.org
-
Huvudutredare:
- Emily Hinchcliff
-
-
Indiana
-
Carmel, Indiana, Förenta staterna, 46032
- Rekrytering
- IU Health North Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 317-278-5632
- E-post: iutrials@iu.edu
-
Huvudutredare:
- Jessica E. Parker
-
Indianapolis, Indiana, Förenta staterna, 46202
- Rekrytering
- Indiana University/Melvin and Bren Simon Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 317-278-5632
- E-post: iutrials@iu.edu
-
Huvudutredare:
- Jessica E. Parker
-
-
Louisiana
-
Marrero, Louisiana, Förenta staterna, 70072
- Rekrytering
- West Jefferson Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 504-210-3539
- E-post: emede1@lsuhsc.edu
-
Huvudutredare:
- Tara Castellano
-
Metairie, Louisiana, Förenta staterna, 70006
- Rekrytering
- East Jefferson General Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 504-210-3539
- E-post: emede1@lsuhsc.edu
-
Huvudutredare:
- Tara Castellano
-
Metairie, Louisiana, Förenta staterna, 70006
- Rekrytering
- LSU Healthcare Network / Metairie Multi-Specialty Clinic
-
Kontakt:
- Site Public Contact
- Telefonnummer: 504-210-3539
- E-post: emede1@lsuhsc.edu
-
Huvudutredare:
- Tara Castellano
-
New Orleans, Louisiana, Förenta staterna, 70112
- Rekrytering
- University Medical Center New Orleans
-
Kontakt:
- Site Public Contact
- Telefonnummer: 504-210-3539
- E-post: emede1@lsuhsc.edu
-
Huvudutredare:
- Tara Castellano
-
New Orleans, Louisiana, Förenta staterna, 70112
- Rekrytering
- Louisiana State University Health Science Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 504-210-3539
- E-post: emede1@lsuhsc.edu
-
Huvudutredare:
- Tara Castellano
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21201
- Rekrytering
- University of Maryland/Greenebaum Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-888-8823
-
Huvudutredare:
- Gautam G. Rao
-
Bel Air, Maryland, Förenta staterna, 21014
- Rekrytering
- UM Upper Chesapeake Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 443-643-3010
-
Huvudutredare:
- Gautam G. Rao
-
-
Michigan
-
Detroit, Michigan, Förenta staterna, 48201
- Rekrytering
- Wayne State University/Karmanos Cancer Institute
-
Huvudutredare:
- Robert T. Morris
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-527-6266
- E-post: ctoadmin@karmanos.org
-
Farmington Hills, Michigan, Förenta staterna, 48334
- Rekrytering
- Weisberg Cancer Treatment Center
-
Huvudutredare:
- Robert T. Morris
-
Kontakt:
- Site Public Contact
- Telefonnummer: 313-576-9790
- E-post: ctoadmin@karmanos.org
-
Flint, Michigan, Förenta staterna, 48532
- Rekrytering
- McLaren Cancer Institute-Flint
-
Huvudutredare:
- Robert T. Morris
-
Kontakt:
- Site Public Contact
- Telefonnummer: 313-576-9790
- E-post: ctoadmin@karmanos.org
-
-
Minnesota
-
Edina, Minnesota, Förenta staterna, 55435
- Rekrytering
- Fairview Southdale Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-post: mmcorc@healthpartners.com
-
Huvudutredare:
- Britt K. Erickson
-
Maple Grove, Minnesota, Förenta staterna, 55369
- Rekrytering
- Fairview Clinics and Surgery Center Maple Grove
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-post: mmcorc@healthpartners.com
-
Huvudutredare:
- Britt K. Erickson
-
Maplewood, Minnesota, Förenta staterna, 55109
- Rekrytering
- Saint John's Hospital - Healtheast
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-post: mmcorc@healthpartners.com
-
Huvudutredare:
- Britt K. Erickson
-
Princeton, Minnesota, Förenta staterna, 55371
- Rekrytering
- Fairview Northland Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-post: mmcorc@healthpartners.com
-
Huvudutredare:
- Britt K. Erickson
-
Saint Paul, Minnesota, Förenta staterna, 55101
- Rekrytering
- Regions Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-post: mmcorc@healthpartners.com
-
Huvudutredare:
- Britt K. Erickson
-
Wyoming, Minnesota, Förenta staterna, 55092
- Rekrytering
- Fairview Lakes Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 952-993-1517
- E-post: mmcorc@healthpartners.com
-
Huvudutredare:
- Britt K. Erickson
-
-
Missouri
-
Springfield, Missouri, Förenta staterna, 65804
- Rekrytering
- Mercy Hospital Springfield
-
Huvudutredare:
- Jay W. Carlson
-
Kontakt:
- Site Public Contact
- Telefonnummer: 417-269-4520
-
-
Montana
-
Billings, Montana, Förenta staterna, 59101
- Aktiv, inte rekryterande
- Saint Vincent Healthcare
-
Billings, Montana, Förenta staterna, 59102
- Aktiv, inte rekryterande
- Saint Vincent Frontier Cancer Center
-
Billings, Montana, Förenta staterna, 59106
- Aktiv, inte rekryterande
- Intermountain Health West End Clinic
-
Butte, Montana, Förenta staterna, 59701
- Aktiv, inte rekryterande
- Saint James Community Hospital and Cancer Treatment Center
-
-
Nebraska
-
Kearney, Nebraska, Förenta staterna, 68845
- Rekrytering
- Fred and Pamela Buffett Cancer Center - Kearney
-
Kontakt:
- Site Public Contact
- Telefonnummer: 402-559-6941
- E-post: unmcrsa@unmc.edu
-
Huvudutredare:
- Kerry J. Rodabaugh
-
Omaha, Nebraska, Förenta staterna, 68198
- Rekrytering
- University of Nebraska Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 402-559-6941
- E-post: unmcrsa@unmc.edu
-
Huvudutredare:
- Kerry J. Rodabaugh
-
Omaha, Nebraska, Förenta staterna, 68118
- Rekrytering
- Nebraska Medicine-Village Pointe
-
Kontakt:
- Site Public Contact
- Telefonnummer: 402-559-5600
-
Huvudutredare:
- Kerry J. Rodabaugh
-
Omaha, Nebraska, Förenta staterna, 68124
- Aktiv, inte rekryterande
- Alegent Health Bergan Mercy Medical Center
-
-
Nevada
-
Las Vegas, Nevada, Förenta staterna, 89106
- Rekrytering
- Women's Cancer Center of Nevada
-
Huvudutredare:
- Nicola M. Spirtos
-
Kontakt:
- Site Public Contact
- Telefonnummer: 702-851-4672
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Förenta staterna, 73104
- Rekrytering
- University of Oklahoma Health Sciences Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 405-271-8777
- E-post: ou-clinical-trials@ouhsc.edu
-
Huvudutredare:
- Christina Washington
-
-
Pennsylvania
-
Bryn Mawr, Pennsylvania, Förenta staterna, 19010
- Upphängd
- Bryn Mawr Hospital
-
Paoli, Pennsylvania, Förenta staterna, 19301
- Upphängd
- Paoli Memorial Hospital
-
Wynnewood, Pennsylvania, Förenta staterna, 19096
- Upphängd
- Lankenau Medical Center
-
-
Rhode Island
-
Providence, Rhode Island, Förenta staterna, 02905
- Rekrytering
- Women and Infants Hospital
-
Huvudutredare:
- Matthew T. Oliver
-
Kontakt:
- Site Public Contact
- Telefonnummer: 401-274-1122
-
-
Texas
-
Dallas, Texas, Förenta staterna, 75390
- Rekrytering
- UT Southwestern/Simmons Cancer Center-Dallas
-
Huvudutredare:
- Jayanthi S. Lea
-
Kontakt:
- Site Public Contact
- Telefonnummer: 214-648-7097
- E-post: canceranswerline@UTSouthwestern.edu
-
Dallas, Texas, Förenta staterna, 75235
- Rekrytering
- Parkland Memorial Hospital
-
Huvudutredare:
- Jayanthi S. Lea
-
Kontakt:
- Site Public Contact
- Telefonnummer: 214-590-5582
- E-post: canceranswerline@UTSouthwestern.edu
-
Fort Worth, Texas, Förenta staterna, 76104
- Rekrytering
- UT Southwestern/Simmons Cancer Center-Fort Worth
-
Huvudutredare:
- Jayanthi S. Lea
-
Kontakt:
- Site Public Contact
- Telefonnummer: 214-648-7097
- E-post: canceranswerline@UTSouthwestern.edu
-
Houston, Texas, Förenta staterna, 77030
- Rekrytering
- Memorial Hermann Texas Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 713-792-3245
-
Huvudutredare:
- Joseph A. Lucci
-
Houston, Texas, Förenta staterna, 77030
- Aktiv, inte rekryterande
- Houston Methodist Hospital
-
Houston, Texas, Förenta staterna, 77070
- Aktiv, inte rekryterande
- Methodist Willowbrook Hospital
-
Houston, Texas, Förenta staterna, 77094
- Aktiv, inte rekryterande
- Houston Methodist West Hospital
-
Richardson, Texas, Förenta staterna, 75080
- Rekrytering
- UT Southwestern Clinical Center at Richardson/Plano
-
Huvudutredare:
- Jayanthi S. Lea
-
Kontakt:
- Site Public Contact
- Telefonnummer: 972-669-7044
- E-post: Suzanne.cole@utsouthwestern.edu
-
Sugar Land, Texas, Förenta staterna, 77479
- Aktiv, inte rekryterande
- Houston Methodist Sugar Land Hospital
-
The Woodlands, Texas, Förenta staterna, 77385
- Aktiv, inte rekryterande
- Houston Methodist The Woodlands Hospital
-
-
Virginia
-
Charlottesville, Virginia, Förenta staterna, 22908
- Rekrytering
- University of Virginia Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 434-243-6303
- E-post: uvacancertrials@hscmail.mcc.virginia.edu
-
Huvudutredare:
- Kari L. Ring
-
-
-
-
-
Incheon, Sydkorea, 405-760
- Rekrytering
- Gachon University Gil Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 82-32-460-3213
-
Huvudutredare:
- Kwang-Beom Lee
-
Seoul, Sydkorea, 05505
- Rekrytering
- Asan Medical Center
-
Kontakt:
- Site Public Contact
- E-post: irbksh@amc.seoul.kr
-
Huvudutredare:
- Dae-Yeon Kim
-
Seoul, Sydkorea, 06273
- Rekrytering
- Gangnam Severance Hospital
-
Huvudutredare:
- Jae-Hoon Kim
-
Kontakt:
- Site Public Contact
- Telefonnummer: 82-2-2019-3600
-
Seoul, Sydkorea, 07985
- Rekrytering
- Ewha Woman's University Mokdong Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 82 2-2650-5114
-
Huvudutredare:
- Yun H. Kim
-
-
Gyeongsangnam-do
-
Seoul, Gyeongsangnam-do, Sydkorea, 51353
- Upphängd
- Samsung Changwon Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
Histologically proven diagnosis of endometrial cancer based on endometrial sampling with a plan to undergo laparoscopic or robotic hysterectomy and lymphatic assessment as part of primary management. Biopsy must be performed within 90 days prior to registration
-
Clinical stage I endometrial cancer based on the following diagnostic workup:
- History/physical examination within 30 days prior to registration is reassuring for the absence of metastatic disease
-
Age >= 18 years
-
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information
-
Patients must speak English, Spanish, or Korean
Exclusion Criteria:
-
Patients whom the surgeon believes is not a candidate for pelvic lymphadenectomy due to medical comorbidities or other technical challenges (i.e. morbid obesity or prior surgery)
-
History of chemotherapy or immunotherapy for the treatment of endometrial cancer. Progestin-containing therapies such as megestrol, medroxyprogesterone, or levonorgestrel-containing intrauterine device (IUD) are acceptable
-
History of radiation to the pelvis, groin or lower extremities, or surgery to the pelvic lymph nodes or inguinal lymph nodes
-
Patients who are going to undergo another elective surgery during the same operative event as their hysterectomy (i.e., sacrocolpopexy, cholecystectomy)
-
Patients with severe, active co-morbidity defined as follows:
- History of patient or provider identified lower extremity lymphedema
- History of patient or provider identified chronic lower extremity swelling
- History of lower extremity or pelvic deep venous thromboembolism within 90 days of registration
- History of lower extremity cellulitis within 90 days of registration
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Stödjande vård
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Arm 1 (sentinel lymph node mapping)
Patients receive ICG dye via injection and undergo sentinel lymph node mapping and excision during standard minimally invasive hysterectomy. Lymph nodes around the uterus may be removed if the mapping and excision cannot be completed. Successful mapping requires no additional removal of lymph nodes. Patients also undergo imaging as clinically indicated and optional blood sample collection throughout the study. |
Undergo blood sample collection
Andra namn:
Ancillary studies Undergo imaging
Andra namn:
Undergo sentinel lymph node excision
Andra namn:
Given via injection
Andra namn:
Undergo minimally invasive hysterectomy
Andra namn:
Undergo pelvic lymphadenectomy
Andra namn:
Undergo sentinel lymph node mapping
Andra namn:
|
|
Experimentell: Arm 2 (sentinel lymph node mapping, pelvic lymphadenectomy)
Patients receive ICG dye via injection and undergo sentinel lymph node mapping and excision during standard minimally invasive hysterectomy. Additional lymph nodes around the uterus are removed per standard of care. Patients also undergo imaging as clinically indicated and optional blood sample collection throughout the study. |
Undergo blood sample collection
Andra namn:
Ancillary studies Undergo imaging
Andra namn:
Undergo sentinel lymph node excision
Andra namn:
Given via injection
Andra namn:
Undergo minimally invasive hysterectomy
Andra namn:
Undergo pelvic lymphadenectomy
Andra namn:
Undergo sentinel lymph node mapping
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Incidence of patient-reported lower extremity limb dysfunction
Tidsram: From 18 months post-hysterectomy after undergoing lymphatic assessment to 39 months
|
The primary endpoint is the incidence of patient-reported lower extremity limb dysfunction at 18 months post-hysterectomy after undergoing lymphatic assessment according to a National Comprehensive Cancer Network guideline-based sentinel lymph node (SLN) mapping algorithm with or without completion of lymphadenectomy. The primary endpoint will be assessed using the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) questionnaire. Surveys will be performed at enrollment (pre-surgery) and at 3, 6, 9, 12, and 18 months post-surgery. Patient-reported lower extremity limb dysfunction will be defined as an increase in GCLQ symptom score of at least four (4) points from baseline at any time during the 18 months follow-up. The primary null hypothesis will be evaluated with an intent-to-treat chi-squared test, adjusted for stratification factors. Proportional hazards modeling will be used to generate a hazard ratio and 95% confidence limits of Arm 1 versus Arm 2. |
From 18 months post-hysterectomy after undergoing lymphatic assessment to 39 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
The incidence of lymphedema by quantifiable lower extremity limb changes
Tidsram: From enrollment and at 3, 6, 9, 12, and 18 months after surgery
|
Patients will undergo circumferential lower extremity limb measures at three locations along each leg. Change will be estimated as measurement at baseline subtracted from measurement at follow-up. This will be assessed in both legs separately. |
From enrollment and at 3, 6, 9, 12, and 18 months after surgery
|
|
Rate of successful bilateral SLN identification
Tidsram: At time of surgery
|
Will be assessed in both, and only as the time of surgery. |
At time of surgery
|
|
Rate of successful identification of lymph node metastasis
Tidsram: At time of surgery
|
Will be assessed in both, and only as the time of surgery. The rate of lymph node metastasis identification during surgery will be compared between groups, with either t-tests or chi-squared tests where appropriate. |
At time of surgery
|
|
Rate of perioperative complications
Tidsram: At time of surgery
|
Will be assessed in both arms separately, and only as the time of surgery. The rate of perioperative complications during surgery will be compared between groups, with either t-tests or chi-squared tests where appropriate. |
At time of surgery
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Adjuvant therapy decisions
Tidsram: Up to 24 months
|
Adjuvant therapy decisions will be compared for patients according to study arm allocation after accounting for tumor characteristics, stage, and patient demographics to determine whether lymph node mapping strategies was associated with a difference in adjuvant therapy choice. |
Up to 24 months
|
|
Patient characteristic, extent of lymph node dissection, and adjuvant therapy decisions
Tidsram: Up to 24 months
|
Patient characteristics (age, body mass index, race), extent of lymph node dissection, and adjuvant therapy decisions (radiation, chemotherapy), will be collected to determine their impact as a covariate on the development of the primary endpoint (lower extremity limb dysfunction). Models adjusting for potential confounders will be fitted and analyzed. |
Up to 24 months
|
|
Progression free survival
Tidsram: The duration of time from study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed at 2 years after enrollment
|
This endpoint is not expected to be sufficiently powered for a definitive comparison and will therefore be treated as supportive evidence. |
The duration of time from study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed at 2 years after enrollment
|
|
Overall survival
Tidsram: Duration of time from study entry to time of death or the date of last contact, assessed at 2 years after enrollment
|
This endpoint is not expected to be sufficiently powered for a definitive comparison and will therefore be treated as supportive evidence. |
Duration of time from study entry to time of death or the date of last contact, assessed at 2 years after enrollment
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Edward J Tanner, NRG Oncology
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer
- Neoplasmer efter histologisk typ
- Sarkom
- Neoplasmer, bindväv och mjukvävnad
- Neoplasmer, komplexa och blandade
- Karcinosarkom
- Heterocykliska föreningar
- Heterocykliska föreningar, 2-ring
- Heterocykliska föreningar, smältring
- Undersökningstekniker
- Kliniska laboratorietekniker
- Diagnostiska tekniker och procedurer
- Diagnos
- Kirurgiska ingrepp, operativ
- Cytologiska tekniker
- Cytodiagnos
- Fysiska fenomen
- Förenad
- Diagnostiska tekniker, kirurgiska
- Elektromagnetiska fenomen
- Magnetfenomen
- Elektromagnetisk strålning
- Strålning
- Strålning, joniserande
- Biopsi
- Provhantering
- Minimalt invasiva kirurgiska ingrepp
- Röntgenstrålar
- Indocyaningrön
Andra studie-ID-nummer
- NRG-CC010
- UG1CA189867 (U.S.S. NIH-anslag/kontrakt)
- NCI-2022-05090 (Registeridentifierare: CTRP (Clinical Trial Reporting Program))
- NRG-CC010 (Annan identifierare: CTEP)
- NRG-CC010 (Annan identifierare: NRG Oncology)
- NRG-CC010 (Annan identifierare: DCP)
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .